Conclusion of a non-exclusive rebate agreement for natalizumab (ILO, ATC L04AA23) for the period 01/09/2026–31/08/2028

Summary

The tender concerns the conclusion of a non-exclusive rebate agreement for medicinal products containing the active substance natalizumab for the period 01/09/2026–31/08/2028. DAK-Gesundheit intends to conclude agreements with as many interested pharmaceutical companies as possible for the medicinal products to be named by the bidder in the contract. This is a supplies procurement, and the machine-readable notice did not include precise participation requirements; these must be checked in the tender documents.